Combo Therapy May Prevent Cancer’s Return After Liver Surgery
MONDAY, April 24, 2023 (HealthDay News) — A two-drug combination therapy can enhance survival odds for people with early-stage liver cancer through targeted attacks on tumor cells, a new clinical trial shows. The combo — atezolizumab (Tecentriq) and bevacizumab (Avastin) — reduced risk of cancer recurrence or death by 28%Continue Reading